The recent identification of a brain CSC subpopulation with potent tumorigenic activity supports such therapy resistance phenotype, which molecular signature can be partially recapitulated in vitro in CD133-enriched neurospheres derived from glioblastoma primary cultures [35]. Here, PROM1 is linked to glioblastoma.